Invention Grant
- Patent Title: Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor
-
Application No.: US17187468Application Date: 2021-02-26
-
Publication No.: US11110087B2Publication Date: 2021-09-07
- Inventor: Deepak Sampath , Christian Klein , Wayne John Fairbrother , Sari L. Heitner Enschede , Rod A. Humerickhouse , Andrew W. Roberts , John F. Seymour
- Applicant: GENENTECH, INC. , HOFFMANN-LA ROCHE INC. , ABBVIE INC.
- Applicant Address: US CA South San Francisco; US NJ Little Falls; US IL North Chicago
- Assignee: GENENTECH, INC.,HOFFMANN-LA ROCHE INC.,ABBVIE INC.
- Current Assignee: GENENTECH, INC.,HOFFMANN-LA ROCHE INC.,ABBVIE INC.
- Current Assignee Address: US CA South San Francisco; US NJ Little Falls; US IL North Chicago
- Agency: Jones Day
- Main IPC: A61K31/496
- IPC: A61K31/496 ; A61P35/02 ; A61P35/00 ; A61K39/395
Abstract:
The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
Public/Granted literature
- US20210177838A1 COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR Public/Granted day:2021-06-17
Information query
IPC分类:
